Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa | Zendy

Tony Hawkridge | Zendy; Thomas J. Scriba | Zendy; Sebastian Gelderbloem | Zendy; Erica Smit | Zendy; Michèle Tameris | Zendy; Sizulu Moyo | Zendy; Trudie Lang | Zendy; Ashley Veldsman | Zendy; Mark Hatherill | Zendy; Linda van der Merwe | Zendy; Helen A. Fletcher | Zendy; Hassan Mahomed | Zendy; Adrian V. S. Hill | Zendy; Willem A. Hanekom | Zendy; Gregory Hussey | Zendy; Helen McShane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa

Author(s) -

Tony Hawkridge,

Thomas J. Scriba,

Sebastian Gelderbloem,

Erica Smit,

Michèle Tameris,

Sizulu Moyo,

Trudie Lang,

Ashley Veldsman,

Mark Hatherill,

Linda van der Merwe,

Helen A. Fletcher,

Hassan Mahomed,

Adrian V. S. Hill,

Willem A. Hanekom,

Gregory Hussey,

Helen McShane

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/590185

Subject(s) - immunogenicity , elispot , vaccination , mycobacterium tuberculosis , immunology , tuberculosis , tuberculosis vaccines , virology , bcg vaccine , medicine , immune system , biology , t cell , pathology

The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research